Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 40,690 Shares

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. bought 40,690 shares of Oncocyte stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average price of $3.88 per share, with a total value of $157,877.20. Following the completion of the acquisition, the insider owned 12,114,700 shares in the company, valued at approximately $47,005,036. The trade was a 0.34% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, April 17th, Broadwood Partners, L.P. bought 40,114 shares of Oncocyte stock. The stock was bought at an average price of $3.57 per share, with a total value of $143,206.98.
• On Thursday, April 16th, Broadwood Partners, L.P. bought 102,057 shares of Oncocyte stock. The stock was bought at an average price of $3.45 per share, with a total value of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. bought 521,739 shares of Oncocyte stock. The stock was bought at an average price of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Stock Performance

Oncocyte stock opened at $3.99 on Tuesday. The firm has a market cap of $128.36 million, a price-to-earnings ratio of -2.46 and a beta of 1.52. Oncocyte Corp has a fifty-two week low of $2.33 and a fifty-two week high of $8.51. The stock’s fifty day moving average price is $4.57.

Oncocyte (NASDAQ:IMDX) last released its earnings results on Thursday, March 26th. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $1.14 million for the quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Wall Street Zen cut shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Lake Street Capital upped their target price on shares of Oncocyte from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.